Sobi has completed the acquisition of AstraZeneca’s Synagis (palivizumab) for $1.5 billion in cash and shares, plus certain conditional payments. As part of the deal, first announced in August ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback